The estimated Net Worth of John Djcp Iii Sm Aiv, L.P.M... is at least $1.99 Milione dollars as of 22 December 2021. Mr M owns over 145,773 units of Petros Pharmaceuticals stock worth over $1,991,107 and over the last 3 years he sold PTPI stock worth over $0.
Sign up
Mr Shulman PTPI stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Petros Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 145,773 units of PTPI stock worth $500,001 on 22 December 2021.
The largest trade he's ever made was buying 1,661,807 units of Petros Pharmaceuticals stock on 18 October 2021 worth over $2,858,308. On average, Mr trades about 769,193 units every 22 days since 2021. As of 22 December 2021 he still owns at least 5,703,544 units of Petros Pharmaceuticals stock.
You can see the complete history of Mr M stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. John D. Shulman biography
John D. Shulman is the Exec. Chairman at Petros Pharmaceuticals.
How old is Mr Shulman?
Mr Shulman is 58, he's been the Exec. Chairman of Petros Pharmaceuticals since . There are 1 older and 4 younger executives at Petros Pharmaceuticals. The oldest executive at Petros Pharmaceuticals, Inc. is Robert Weinstein, 61, who is the Interim Chief Financial Officer.
Insiders trading at Petros Pharmaceuticals
Over the last 4 years, insiders at Petros Pharmaceuticals have traded over $0 worth of Petros Pharmaceuticals stock and bought 2,307,580 units worth $4,858,309 . The most active insiders traders include John Djcp Iii Sm Aiv, L.P.M..., Bruce Bernstein e Joshua Silverman. On average, Petros Pharmaceuticals executives and independent directors trade stock every 50 days with the average trade being worth of $74,319. The most recent stock trade was executed by Greg Bradley on 26 April 2023, trading 6,050 units of PTPI stock currently worth $2,112.
What does Petros Pharmaceuticals do?
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
What does Petros Pharmaceuticals's logo look like?
Complete history of Mr M stock trades at Petros Pharmaceuticals
Petros Pharmaceuticals executives and stock owners
Petros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Fady Boctor M.B.A.,
Pres & Chief Commercial Officer -
Mitchell S. Arnold M.B.A.,
VP of Fin. & Chief Accounting Officer -
Andrew Gesek M.B.A.,
Pres of Timm Medical Technologies -
Robert Weinstein,
Interim Chief Financial Officer -
Keith F. Lavan,
Advisor -
John D. Shulman,
Exec. Chairman -
Mitchell Arnold,
See Remarks -
Fady Boctor,
See Remarks -
Joshua Silverman,
Director -
Keith Lavan,
Chief Financial Officer -
Therapeutics, Llc Metuchen,
10% owner -
John Djcp Iii Sm Aiv, L.P.M...,
-
Andrew Gesek,
President, Timm Medical -
Wayne Remell Walker,
Director -
John D Shulman,
Director -
Bruce Bernstein,
Director -
Greg Bradley,
Director